

# REMOVED: P57 NIMOTUZUMAB IN COMBINATION WITH DOCETAXEL AND CARBOPLATIN AS TREATMENT FOR ADVANCED NON-SMALL-CELL-LUNG-CANCER

D. Qi<sup>a</sup>, Q. Wang<sup>a</sup>, C. Huang<sup>a</sup>, Y. Li<sup>a</sup>, Y. Yang<sup>a</sup>, Y. Cui<sup>a</sup>, L. Xin<sup>a</sup>, J. Xu<sup>a</sup>, H. Wang<sup>a</sup>, J. Zheng<sup>\*,b,c</sup>

<sup>a</sup>Key Laboratory of Cancer Prevention and Therapy, Department of First-Class Ward, Cancer Hospital, Tianjin Medical University, Tianjin, China, <sup>b</sup>Biotech Pharmaceuticals Co. Ltd., China, <sup>c</sup>Medical School, Tongji University, Shanghai, China

This article has been removed: please see Elsevier Policy on Article Withdrawal (<http://www.elsevier.com/locate/withdrawalpolicy>).

This abstract has been removed at the request of the Editor-in-Chief and author because it contains a drug dosage error which could have serious health consequences. The abstract contained a dosage error for the drug, docetaxel.

The corrected abstract should read as follows:

**Background:** We evaluated the efficacy of nimotuzumab combined with docetaxel and carboplatin (TP) for treatment of advanced non-small-cell-lung-cancer (NSCLC), as well as the effect on circulating blood markers and patient's side-effects.

**Methods:** 21 patients with advanced NSCLC were enrolled in the study. Patients were given nimotuzumab (200 mg/week for 6 weeks) and DP regimen (60 mg/m<sup>2</sup> docetaxel and 400 mg/m<sup>2</sup> carboplatin, twice). Each patient had two cycles of chemotherapy. Response data was collected before and after treatment. Tumour size and reduction were recorded by thoracic CT scan and compared. Treatment related side-effects were compared by statistical methods.

**Findings:** Tumour size and levels of CEA, NSE, and CYFR21-1 were decreased after treatment ( $p=0.01$ ,  $p=0.02$ ,  $p=0.03$ ). Four patients had a complete response, five had a partial response, nine had stable disease, and three had progressive disease. Three patients had side-effects on facial skin and were graded as stage I–II disease.

**Interpretation:** Nimotuzumab combined with DP regimen may increase the efficacy of treatment, with few side-effects.

**Funding:** Beijing Science Plan.

The authors declared no conflicts of interest.